Universal Beteiligungs und Servicegesellschaft mbH Reduces Stock Position in Humana Inc. $HUM

Universal Beteiligungs und Servicegesellschaft mbH lessened its stake in shares of Humana Inc. (NYSE:HUM) by 11.7% in the fourth quarter, HoldingsChannel reports. The firm owned 72,042 shares of the insurance provider’s stock after selling 9,562 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Humana were worth $18,560,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. CoreCap Advisors LLC grew its holdings in shares of Humana by 54.4% during the fourth quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock worth $27,000 after buying an additional 37 shares in the last quarter. Rosenberg Matthew Hamilton lifted its stake in shares of Humana by 136.0% during the fourth quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock valued at $30,000 after buying an additional 68 shares during the period. Mather Group LLC. purchased a new position in shares of Humana during the third quarter valued at approximately $34,000. Private Wealth Management Group LLC lifted its stake in shares of Humana by 47.5% during the third quarter. Private Wealth Management Group LLC now owns 149 shares of the insurance provider’s stock valued at $39,000 after buying an additional 48 shares during the period. Finally, Larson Financial Group LLC lifted its stake in shares of Humana by 114.1% during the third quarter. Larson Financial Group LLC now owns 152 shares of the insurance provider’s stock valued at $40,000 after buying an additional 81 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Analyst Upgrades and Downgrades

HUM has been the topic of several recent analyst reports. Guggenheim reduced their price objective on shares of Humana from $312.00 to $252.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. Barclays reduced their price objective on shares of Humana from $245.00 to $176.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 24th. Leerink Partners reduced their price objective on shares of Humana from $267.00 to $185.00 and set a “market perform” rating on the stock in a research note on Thursday, February 12th. Robert W. Baird reduced their price objective on shares of Humana from $264.00 to $205.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 15th. Finally, Jefferies Financial Group reduced their price objective on shares of Humana from $310.00 to $235.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. Seven equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $222.09.

Insider Buying and Selling at Humana

In related news, insider Sanjay K. Shetty purchased 810 shares of the firm’s stock in a transaction on Monday, February 23rd. The shares were bought at an average price of $185.21 per share, for a total transaction of $150,020.10. Following the acquisition, the insider directly owned 11,657 shares in the company, valued at $2,158,992.97. This trade represents a 7.47% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link. 0.20% of the stock is currently owned by company insiders.

Humana Stock Performance

NYSE:HUM opened at $215.26 on Friday. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 0.70. The company has a market cap of $25.84 billion, a P/E ratio of 21.92, a P/E/G ratio of 2.30 and a beta of 0.44. Humana Inc. has a fifty-two week low of $163.11 and a fifty-two week high of $315.35. The firm’s 50 day moving average is $184.64 and its two-hundred day moving average is $229.11.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.01) by $0.05. The company had revenue of $32.64 billion for the quarter, compared to analyst estimates of $32.08 billion. Humana had a net margin of 0.92% and a return on equity of 11.43%. Humana’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same quarter last year, the business earned ($2.16) EPS. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. Analysts expect that Humana Inc. will post 9.05 EPS for the current year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be issued a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.6%. The ex-dividend date is Friday, June 26th. Humana’s dividend payout ratio (DPR) is 36.05%.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.